Clinical Trial Update: A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma [Phase 1]

View source ↗

Summary

This update describes an open Phase 1 trial evaluating TTI-622 in combination with Daratumumab Hyaluronidase-fihj for multiple myeloma, currently active and not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab Hyaluronidase-fihj (daratumumab; hyaluronidase-fihj)
• TTI-622 (TTI-622)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING